1,2-Dihydroellipticines with Activity Against CNS-Specific Cancer Cell Lines
Description of Invention:
The present invention is directed, in general, to methods for treating human cancers and in particular to new compounds which cross the blood brain barrier and retain activity against CNS specific cancer cell lines, to pharmaceutical formulations containing such compounds, and to methods for the treatment of cancer.
The 2-methylellipticinium salts offer remarkable examples of compounds that have shown selective cytotoxicity for the CNS cancer cell lines. In 17 assays, 6 showed selectivity for the CNS subpanel at every level of the dose-response curve down to 10-7M. Both the 9-methyl and the 9-chloro analogues also displayed good CNS selectivity at the levels for growth inhibition and cytostasis.
Inventors:
Rudiger D. Haugwitz (NCI) et al.
Patent Status:
DHHS Reference No. E-110-1992/0 --
U.S. Patent No. 5,272,146 issued 21 Dec 1993
U.S. Patent No. 5,441,941 issued 15 Aug 1995
Relevant Publication:
This research is described, in part, in Jurayj et al., "Design and Synthesis of Ellipticinium Salts and 1,2-Dihydroellipticines with High Selectivities against Human CNS Cancers in vitro," J. Med. Chem. 37(14):2190-2197, 1994.
Portfolios: Cancer
Cancer -Therapeutics-Conventional Chemotherapy-Other Cancer -Therapeutics
For Additional Information Please Contact: Adaku Nwachukwu J.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: 301 435-5560
Email: madua@mail.nih.gov
Fax: 301 402-0220
